Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This trial will evaluate long term safety of participants who have received GlaxoSmithKline
(GSK) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Phase
Phase 1
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Enrollment Eligibility
Inclusion Criteria:
- Participants who have received at least one dose of GSK adoptive cell therapy agent.
- Participants who have completed GSK sponsored or supported interventional study or
have withdrawn from it.
- Participants who have completed treatment as part of managed access to a GSK adoptive
cell therapy.
- Contraceptive use by men or women should be consistent with local regulations
regarding the methods of contraception for those participating in clinical studies.
- The investigator is responsible for review of medical history.
- Capable of giving signed informed consent.
Exclusion Criteria:
- None